Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
Ermium Therapeutics bags €6.3m in Series A round
Latest NewsParis-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
Pharvaris BV raises $66m to advance oral HAE drug
Latest NewsLeiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
4BIO Ventures launches US$50m fund
Latest NewsLondon and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.
PDC*line Pharma welcomes Dr Channa Debruyne
AppointmentsPDC*line Pharma, a clinical stage biotech company developing a new class of immunotherapies for cancers announced today that Dr Channa Debruyne joined the company in August as medical director to lead the clinical research team.
ADC Therapeutics set to go public
Latest NewsAntibody drug conjugate expert ADC Therapeutics SA has filed a Registration Statement for an Initial Public Offering with the US Securities and Exchange Commission.
iStar Medical SA raises €40.1m
Latest NewsGlucoma transplant specialist iStar Medical SA has closed a Series C finanincing round led by LSP and Gimv.
Avillion appoints Dr Anders Gersel Pedersen
AppointmentsAvillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
UniQure looking to raise US$200m
Latest NewsDutch gene therapy company UniQure has launched a US$200m stock offering on Nasdaq.
MS: Polpharma joins forces with Sandoz
Latest NewsPolpharma Biologics SA has partnered up with Novartis subsidiary Sandoz AG to market a natalizumab biosimilar. As part of the global commercialization agreement, Polpharma Biologics will be responsible for the development, manufacturing and supply of the collaboration biosimilar, which is currently in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Boehringer and Zealand to advance obesity drug
Latest NewsGerman pharma company Boehringer Ingelheim said the phase II trial for candidate drug BI456906 is expected to be initiated in late 2019 triggering a €20m milestone payment to Zealand Pharma A/S.